| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | CART 1; CART1; cysteine rich domain associated with ring and TRAF domain; Cysteine rich domain associated with RING and Traf domains protein 1; Cysteine-rich domain associated with RING and Traf domains protein 1; Malignant 62; Metastatic lymph node gene 62 protein; MLN 62; MLN62; RING finger protein 83; RNF 83; RNF83; TNF receptor associated factor 4; TNF receptor-associated factor 4; TRAF 4; Traf4; TRAF4_HUMAN; tumor necrosis receptor-associated factor 4A |
| Antigen | |
| Clonality | |
| Conjugate | |
| Form | Liquid |
| Host | |
| Immunogen | Human TRAF4 |
| Isotype | |
| Product Type | |
| Reactivity | |
| Source | This product is a polyclonal antibody purified from rabbit antiserum. |
| Storage | |
| Target | |
| UniProt # |
Product Overview
Primary AntibodyThis antibody targets TRAF4 and was raised against a recombinant protein immunogen.
Validated Applications
| Application | Recommended Dilution |
|---|---|
| ELISA | Refer to datasheet |
| Western Blot (WB) | Refer to datasheet |
| Immunohistochemistry (IHC) | Refer to datasheet |
Antibody Specifications
| Target | TRAF4 |
|---|---|
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Conjugate | Unconjugated |
| Reactivity | Human, Mouse, Rat |
| Purification | Affinity Purification |
| Antigen / Immunogen | Human TRAF4 |
| Production | This product is a polyclonal antibody purified from rabbit antiserum. |
| Form | Liquid |
| Storage Buffer | PBS, 0.1% sodium azide, 50% glycerol, pH 7.3. |
| Storage | Upon receipt, store at -20°C or -80°C. Avoid repeated freeze. |
Alternative Names
CART 1; CART1; cysteine rich domain associated with ring and TRAF domain; Cysteine rich domain associated with RING and Traf domains protein 1; Cysteine-rich domain associated with RING and Traf domains protein 1; Malignant 62; Metastatic lymph node gene 62 protein; MLN 62; MLN62; RING finger protein 83; RNF 83; RNF83; TNF receptor associated factor 4; TNF receptor-associated factor 4; TRAF 4; Traf4; TRAF4_HUMAN; tumor necrosis receptor-associated factor 4A
Safety & Handling
| Target | TRAF4 |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Conjugate | Unconjugated |
| Reactivity | Human, Mouse, Rat |
| Purification | Affinity Purification |
| Antigen/Immunogen | Human TRAF4 |
| Production | This product is a polyclonal antibody purified from rabbit antiserum. |
| Form | Liquid |
| Storage Buffer | PBS, 0.1% sodium azide, 50% glycerol, pH 7.3. |
| Storage | Upon receipt, store at -20°C or -80°C. Avoid repeated freeze. |
Dilutions are starting recommendations. Titration is advised for each system.
| Application | Recommended Dilution |
|---|---|
| ELISA | Refer to datasheet |
| Western Blot (WB) | Refer to datasheet |
| Immunohistochemistry (IHC) | Refer to datasheet |
Immunogen: Human TRAF4
Antigen Species: Human
Alternative Names
CART 1; CART1; cysteine rich domain associated with ring and TRAF domain; Cysteine rich domain associated with RING and Traf domains protein 1; Cysteine-rich domain associated with RING and Traf domains protein 1; Malignant 62; Metastatic lymph node gene 62 protein; MLN 62; MLN62; RING finger protein 83; RNF 83; RNF83; TNF receptor associated factor 4; TNF receptor-associated factor 4; TRAF 4; Traf4; TRAF4_HUMAN; tumor necrosis receptor-associated factor 4A
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
